17.64%| YTD | 1Yr | 3Yr | 5Yr | 10Yr | |
| Fund | 17.64 | 40.83 | -0.12 | 7.78 | 11.70 |
| Classification | 16.41 | 37.20 | -0.77 | 3.55 | 6.13 |
| Index (S&P 500) | 23.50 | 48.80 | -5.90 | 0.70 | -0.90 |
| % Rank in Class (1-best,100=worst) | 42 | 36 | 42 | 8 | 8 |
| Investment Objective: | Health/Biotech |
|---|---|
| Net Assets ($Mil) | 258.00 |
| Inception Date: | 6/30/99 |
| Manager Name, Tenure | Team Managed, NA |
| Expense Ratio: | 1.19% |
|
Sales Charge:
Load Type:
|
Front-End Load 5.50% 0.00% |
| Company Name | Symbol | % Net Assets |
|---|---|---|
| Amag Pharmaceuticals Inc | AMAG | 4.75 |
| Vertex Pharma | VRTX | 4.42 |
| Alexion Pharm | ALXN | 4.10 |
| Shire Plc | SHPGY | 3.77 |
| Allos Therapeutics Inc | ALTH | 3.55 |
| Celgene Corp | CELG | 3.42 |
| Biomarin Pharmaceutical Inc | BMRN | 3.31 |
| Mylan | MYL | 3.04 |
| Incyte Corp | INCY | 2.99 |
| Gilead Sciences Inc | GILD | 2.96 |
| % of Total Holdings | 36.31 | |